Search

Aim: Chemotherapy-induced alopecia (CIA) is the most common side effect of systemic treatment in breast cancer patients. Scalp cooling gained worldwide acceptance in preventing or mitigating CIA in patients undergoing chemotherapy. The objective of this study was to evaluate the efficacy and safety of the Paxman scalp cooling system (PSCS) in Indian breast cancer patients. Materials and Methods: This is a multi-centre, retrospective-observational study including patients registered from 1st March, 2019 to 30th April, 2021 undergoing chemotherapy for breast cancer by using PSCS. The primary end-point was the incidence of CIA after completing cycles of chemotherapy. Results: A total of 91 female patients were enrolled in the study, with a median age of 53 years (IQR: 44-62 years). The prevention of alopecia (grade 0 and grade I) was seen in 81%, while more than 50% hair loss (grade 2) was seen in 16.48% after completion of treatment. The univariate analysis results showed that CIA was significantly higher in patients who received anthracyclines (OR: 2.69; 95% CI: 1.04-6.958; P = 0.041) and in patients with a post-infusion cooling time of >150 minutes (OR: 8.409; 95% CI: 2.295-30.787; P = 0.001). The incidence of grade 2 (>50% hair loss) alopecia was 81.3% in patients <6 weeks and was 18.8% at >6 weeks of start of chemotherapy (P < 0.0001). No adverse events were reported in 71.4% of patients, and the most common adverse event was headache (18.7%). Conclusion: PSCS is an effective and well-tolerated treatment modality for preventing CIA among breast cancer patients undergoing chemotherapy. [ABSTRACT FROM AUTHOR]

Introduction The heterogeneous nature of breast cancer is depicted with genotypic and phenotypic diversity. Her2neu positivity is seen in 15-20% of the breast cancers and is associated with increased tumour aggressiveness with decreased DFS and OS. Molecular subclassification of breast cancer is increasingly emphasized in the personalized care of breast cancer. We evaluated the role of Her2neu expression or amplification in prognosticating breast cancer. Methods and materials We retrospectively evaluated 192 breast cancer patients at our institute from 1st January 2008 to 31st The patients were subcategorized into four groups, namely: hormone receptor positive group(ER+PR+ Her2neu0), Triple positive group, triple negative group and the ER0PR0 Her2neu+ group. The prevalence of high Ki67, grade 3 tumours and lymph node positivity was noted across all the groups. The 5 yr OS and 5 yr PFS was calculated in each group. Results The prevalence of high Ki67 and grade 3 tumours was highest in the triple negative breast cancer group (87.5%, 83.3%) followed by ER0PR0 Her2neu+ group (84.4%, 78.1%), triple positive group (72.7%, 63.6%) and in the ER+PR+Her2neu0 group (38.2%, 35.3%). The 5 yr OS was highest (92%) in the ER+PR+ Her2neu0 group followed by ER0PR0 Her2neu + group(72%), triple positive group (68%) and least was in the triple negative group (39%). The 5 yr PFS was 86% in the ER+PR+ Her2neu0 group, followed by 61% in the ER0PR0 Her2neu+ disease, 56% in the triple positive group and 24% in the triple negative breast cancer. The 5 yr OS and 5 yr PFS was statistically significant (p [ABSTRACT FROM AUTHOR]